Phase 1/2 Study of IPG7236 and Toripalimab in Advanced Solid Tumors Initiated
Nanjing Immunophage Biotech has initiated Phase 1/2 clinical trial evaluating IPG7236 in combination with Toripalimab for advanced solid tumors.
Company
Pharmaceutical intelligence for Nanjing Immunophage Biotech with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.